Key takeaways
- • Trial: AWARD-7 (NCT01621178) — Phase 3, 577 participants over 52 weeks.
- • Drug studied: Trulicity (Dulaglutide) — FDA-approved branded product.
- • Primary endpoint: Change in HbA1c from baseline to week 26 in adults with type 2 diabetes and moderate-to-severe chronic kidney disease
- • Key result: HbA1c reduction 1.2% (1.5mg) and 1.1% (0.75mg) on dulaglutide vs 1.1% on insulin glargine in adults with CKD
- • Published: The Lancet Diabetes & Endocrinology, 2018.
Study design
AWARD-7 was a phase 3 randomized controlled trial enrolling 577 participants over 52 weeks. The trial studied Trulicity (Dulaglutide) for type 2 diabetes and was published in The Lancet Diabetes & Endocrinology in 2018.
Primary endpoint
Change in HbA1c from baseline to week 26 in adults with type 2 diabetes and moderate-to-severe chronic kidney disease
Key results
| Measure | Value |
|---|---|
| Headline result | HbA1c reduction 1.2% (1.5mg) and 1.1% (0.75mg) on dulaglutide vs 1.1% on insulin glargine in adults with CKD |
| HbA1c reduction (highest dose arm) | -1.20 percentage points |
| Participants | 577 |
| Duration | 52 weeks |
| Phase | Phase 3 |
Citation
AWARD-7. Published in The Lancet Diabetes & Endocrinology, 2018.
GLP1Zoom did not conduct this trial. We summarize published primary literature. For verbatim methods and full results, consult the primary publication and the ClinicalTrials.gov registry record.
Related
- Trulicity drug page — pricing, FDA status, side effects, alternatives
- All dulaglutide trials
- GLP-1 clinical trials database
Other Trulicity trials
- REWIND — 12% relative risk reduction in MACE on dulaglutide 1
Important: This trial was conducted on the FDA-approved branded product Trulicity. Compounded versions of Dulaglutide have NOT been studied in equivalent randomized controlled trials, and their efficacy and safety profile may differ.
GLP1Zoom is an affiliate-only comparator. We cite published trials; we do not conduct them. This page is informational and is not a substitute for personalized medical advice — always confirm any treatment decision with your prescribing clinician. Full disclaimer.